Cipla (EU) Limited, UK, a wholly-owned subsidiary of Cipla Limited, has entered into a strategic collaboration with Kemwell Biopharma Private Limited and Manipal Education & Medical Group, marking the inception of a joint venture in the United States. This alliance aims to develop and commercialize novel cell therapy products, addressing major unmet medical needs in […]
Cipla Limited, a leading pharmaceutical company, has announced its decision to further invest approximately INR 42 crore in digital tech company GoApptiv Private Limited. This investment aligns with Cipla’s strategic vision to bolster its presence across the healthcare continuum, particularly in underserved regions, by enhancing access to essential treatments. With the completion of this deal, […]
In a strategic move that amplifies its commitment to the Over-The-Counter (OTC) business, Cipla South Africa, a 100% owned subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA EQ), has signed a binding term sheet to acquire Actor Pharma (Pty) Limited. This acquisition positions Cipla as a leading healthcare player in South Africa, targeting growth opportunities […]
Cipla Limited has reported a profit after tax (PAT) of INR 711 crores for the second quarter of the fiscal year 2022 (Q2 FY22), a 7% increase compared to INR 665 crores for the same quarter of the previous fiscal year. The income from operations of the Indian pharma company for Q2 FY22 was INR […]
Cipla Limited has entered into a joint venture (JV) agreement with Kemwell Biopharma, a Bengaluru-based biopharma contract development and manufacturing organization (CDMO), for developing, manufacturing, and commercializing biosimilars for global markets. The Indian pharma company said that a joint venture company will be incorporated in this connection with an objective to foray into the respiratory […]
Roche India said that India’s Central Drugs Standards Control Organisation (CDSCO) has granted an emergency use authorisation (EUA) for the Casirivimab, Imdevimab antibody cocktail for the treatment of Covid-19. The EUA will now allow Roche to import the globally manufactured product batches of Casirivimab/Imdevimab to India, which will be marketed and distributed in the country […]
Cipla announced that its partner Stempeutics Research has secured regulatory approval from the Drug Controller General of India (DCGI) for the launch of Stempeucel, a cell therapy for the treatment of critical limb ischemia (CLI), in India. Stempeucel has been indicated for the treatment of the condition caused by Buerger’s Disease and Atherosclerotic Peripheral Arterial […]